BMY
Bristol-Myers Squibb Company (BMY) reported revenue of $48.19B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $48.19B | -0.2% |
| FY 2024 | $48.30B | +7.3% |
| FY 2023 | $45.01B | -2.5% |
| FY 2022 | $46.16B | -0.5% |
| FY 2021 | $46.38B | +9.1% |
| FY 2020 | $42.52B | +62.6% |
| FY 2019 | $26.14B | +15.9% |
| FY 2018 | $22.56B | +8.6% |
| FY 2017 |
Bristol-Myers Squibb Company (BMY) reported revenue of $48.19B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Bristol-Myers Squibb Company's revenue grew from $21.24B to $48.19B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $20.78B |
| +6.9% |
| FY 2016 | $19.43B | +17.3% |
| FY 2015 | $16.56B | +4.3% |
| FY 2014 | $15.88B | -3.1% |
| FY 2013 | $16.39B | -7.0% |
| FY 2012 | $17.62B | -17.1% |
| FY 2011 | $21.24B | - |